Mode
Text Size
Log in / Sign up
N/A Completed N=11 Treatment

Evaluation of Procedural Analgesia for Liposonix Treatment

Body Contouring
Source: ClinicalTrials.gov NCT01993238 ↗
Enrolled (actual)
11
Serious AEs
9.1%
Results posted
Apr 2014
Primary outcomePrimary: Pain Score for Overall Treatment — 6.3 units on a scale

Summary

The objectives of this study are to evaluate the safety and effectiveness of procedural analgesia for improvements in tolerability of treatment with the Liposonix System.

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score for Overall Treatment
6.3
SECONDARY
Safety Assessment
SECONDARY
Pain Scores Reported at 1-day Post-Treatment
2.1

Eligibility Criteria

Inclusion Criteria

  • Subject is an adult female or male, 18 to 65 years of age.
  • Subject must weigh more than 120 pounds.
  • Subject must have a Body Mass Index of ≤ 30 kg/m2.
  • Subject must have thickness of skin + subcutaneous adipose tissue in the anticipated treatment area of ≥ 2.3 cm.
  • Subject must be able to read, write, speak, and understand English.

Exclusion Criteria

  • Female subject who is pregnant, is suspected to be pregnant, or is lactating
  • Subjects diagnosed with coagulation disorders or are receiving anticoagulant therapy or medications or dietary supplements which impede coagulation or platelet aggregation
  • Subject has diabetes or cardiovascular disease
  • Subject has had any aesthetic procedure to the region to be treated within past 6 months
  • Subject has systemic skin disease or skin disease in the area to be treated
  • Subject has any abnormality of the skin or soft tissues of the abdominal wall in the area to be treated
  • Subject has had previous open or laparoscopic surgery in the anticipated treatment area
  • Subjects is on prescription or over the counter weight reduction medication or programs, or had weight reduction procedures
  • Subject has skin or superficial tissue that does not lie flat on its own when the subject is in the supine position
  • Subjects undergoing chronic steroid or immunosuppressive therapy
  • Subjects who have cardiac pacemakers or any implantable electrical device
  • Subjects who have metal implants of any type in the area to be treated
  • History of cancer
  • Subjects who have sensory loss or dysesthesia in the area to be treated
  • Subjects taking chronic benzodiazepines or opiates
  • Subjects with a history of severe nausea/vomiting with opioid analgesics
  • Subjects with sleep apnea
  • Subjects with known allergies or sensitivities to study drugs
  • Subjects with liver disease
  • Subjects with renal failure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01993238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search